Market Overview

Morgan Stanley Reiterates Equal-Weight, Lowers PT On Veracyte As Expectations Are Now Better Calibrated


In a report published Friday, Morgan Stanley analyst Steve Beuchaw reiterated an Equal-Weight rating on Veracyte Inc. (NASDAQ: VCYT), but lowered the price target from $10.00 to $9.00.

In the report, Morgan Stanley noted, "Despite lower guidance and a higher share count, shares remain inexpensive relative to growth. Organic growth of 40% in '16Eis among the fastest in the group and supports a 2.6x '16E multiple; updated PT $9 from $10."

Veracyte closed on Thursday at $8.30.

Latest Ratings for VCYT

Jul 2019Initiates Coverage OnBuy
Jul 2019Initiates Coverage OnBuy
Nov 2018DowngradesBuyNeutral

View More Analyst Ratings for VCYT
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Steve BeuchawAnalyst Color Price Target Analyst Ratings


Related Articles (VCYT)

View Comments and Join the Discussion!

Latest Ratings

VRTXCantor FitzgeraldMaintains229.0
HCMCLSAInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Oppenheimer Upgrades Pier 1 Imports To Outperform

RBC Capital Downgrades Campus Crest Communities To Underperform